Figure 1.

FOXM1 expression is regulated by the AKT pathway in AML. (A) Direct inhibition of AKT with MK-2206 results in FOXM1 suppression. Cells were treated with indicated concentrations of MK-2206 for 24 hours, total protein samples were purified immediately after treatment and analyzed via immunoblotting with indicated antibodies, β-actin was used as an internal loading control. (B) AKT inhibition causes downregulation of FOXM1 target genes expression. KG-1 cells were treated with 30 μM MK-2206 for 24 hours, total RNA was purified immediately after treatment and analyzed via RT-qPCR. Data are presented as individual data points and means ± S.D., statistical significance is evaluated for Log₂-transformed data using two-tailed Student’s t-test with Welch’s correction (*p < 0.05, **p < 0.01, ***p < 0.001 for N = 4). (C) Inhibition of PI3K with LY294002 results in suppression of both AKT phosphorylation and FOXM1 levels. Cells were treated with indicated concentrations of LY294002 for 24 hours, total protein samples were purified immediately after treatment and analyzed via immunoblotting with indicated antibodies, β-actin was used as an internal loading control. (D) MK-2206 treatment of KG-1 cells suppresses genetic signatures of FOXM1 target PLK1 and DNA damage response regulators. KG-1 cells were treated with 30 μM MK-2206 for 24 hours, total RNA was purified immediately after treatment and analyzed via RNA-seq. NES, normalized expression score; FDR, false discovery rate.